.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical consequence of 11 months, people with metastatic gastrointestinal tumors that obtained biomarker-matched treatments based upon flowing tumor DNA profiling presented a higher professional advantage than those obtaining unequaled therapy.